CoQ10 Shows Promise for Brain Health but Evidence Remains Mixed

As global populations age rapidly—with 22% of people projected to be over 60 by 2050—age-related cognitive decline is becoming a major public health challenge. Inflammation, oxidative stress, mitochondrial dysfunction, and reduced cerebral blood flow are key contributors to neurodegeneration. This 2025 narrative review by Nankivell and colleagues from Swinburne University evaluates the available evidence on CoQ10 supplementation as a potential cognitive intervention, synthesizing findings from animal research and human clinical trials.

CoQ10 is a naturally occurring, fat-soluble antioxidant found predominantly in mitochondria. Its primary role is shuttling electrons within the electron transport chain to generate ATP—the cell's energy currency. Endogenous CoQ10 levels decline with age, coinciding with increased reactive oxygen species (ROS) production. Two main forms exist: ubiquinone (oxidized) and ubiquinol (reduced), with ubiquinol demonstrating superior bioavailability. The review first establishes CoQ10's well-documented cardiovascular benefits—reducing blood pressure, improving heart failure outcomes, and increasing cerebral blood flow—as a plausible indirect pathway through which CoQ10 might protect cognitive function.

In animal and in vitro studies, the evidence is notably favorable. Across rat and mouse models of Alzheimer's disease, aging, Parkinson's disease, and other neurological conditions, CoQ10 supplementation consistently reduced oxidative stress markers, lowered amyloid plaque burden, suppressed neuroinflammation, restored mitochondrial function, and improved performance on spatial memory and learning tasks such as the Morris water maze. Particularly compelling were findings showing CoQ10 inhibited microglial activation, reduced carbonyl density in brain tissue, and elevated ATP levels in hippocampal and cortical regions—core mechanisms relevant to human neurodegeneration.

The human clinical trial evidence is more mixed. Of 8 randomized controlled trials identified—2 in healthy subjects and 6 in disease populations—4 demonstrated measurable cognitive benefits from CoQ10 supplementation, either alone or in combination with other compounds. Two additional trials reported increases in cerebral blood flow, a known correlate of cognitive performance. Notably, positive findings appeared most consistently in populations with cardiovascular disease or metabolic dysfunction, where CoQ10's effects on energy metabolism and vascular function may be most pronounced. Null results were also reported, particularly in healthy older adults.

The authors attribute the inconsistency across human trials to several key factors: heterogeneous study populations, short supplementation durations, inadequate cognitive test batteries, and critically, differences in CoQ10 formulation and bioavailability. Whether CoQ10 can cross the blood-brain barrier remains incompletely resolved, though one in vitro study identified lipoprotein-mediated uptake and efflux mechanisms at the BBB, suggesting brain penetration may be possible under certain conditions or with targeted delivery strategies.

The review concludes that while biological plausibility and animal data are encouraging, definitive evidence from rigorous human trials is lacking. Future research should prioritize standardized cognitive assessments, high-bioavailability formulations (particularly ubiquinol), longer supplementation durations, and mechanistic biomarker endpoints. CoQ10 remains a scientifically credible but not yet proven intervention for age-related cognitive decline.